Table 1 Baseline clinical characteristics of all patients
From: Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer
Characteristics | Number of Patients (n) | Percentage (%) |
|---|---|---|
Age (years) | ||
  ≥ 50 | 58 | 40.3 |
  < 50 | 86 | 59.7 |
Tumor stage | ||
 T1–2 | 68 | 47.2 |
 T3–4 | 73 | 50.7 |
 Unknown | 3 | 2.1 |
ER status | ||
 Postive | 102 | 70.8 |
 Negative | 42 | 29.2 |
PR status | ||
 Positive | 114 | 79.2 |
 Negative | 30 | 20.8 |
HER2 expression | ||
 Positive | 52 | 36.1 |
 Negative | 92 | 63.9 |
Ki67 status | ||
 Low expression | 33 | 22.9 |
 High expression | 103 | 71.5 |
 unkown | 8 | 5.6 |
Subtype | ||
 Luminal A-like | 12 | 8.3 |
 Luminal B-like | 108 | 75 |
 HER2 positive (non lumninal) | 9 | 6.3 |
 Triple negative | 15 | 10.4 |
Pathological response | ||
 Complete response (include near pCR) | 54 | 37.5 |
 Partial response | 83 | 57.6 |
 Stable disease | 7 | 4.9 |
 Progression disease | 0 | 0 |